Selectins and their carbohydrate ligands mediate the homing of hematopoietic stem/progenitor cells (HSPCs) to the bone marrow. We have previously shown that ex vivo fucosylation of selectin ligands on HSPCs by α1,3 fucosyltransferase VI (FUT6) leads to improved human cord blood (CB)-HSPC engraftment in non-obese diabetic (NOD)/severe combined immune deficient (SCID) mice. In the present study, we determined whether surface fucosylation with α1,3 fucosyltransferase VII (FUT7), which is primarily expressed by hematopoietic cells, improves the function of selectin ligands on CB-HSPCs in comparison with FUT6. A saturating amount of either FUT6 or FUT7, which generates comparable levels of expression of fucosylated epitopes on CB CD34 + cells, was used for these experiments. In vitro, FUT7-treated CB CD34 + cells exhibited greater binding to P-or E-selectin than that of FUT6-treated CB CD34 + cells under static or physiological flow conditions. In vivo, FUT7 treatment, like FUT6, improved the early engraftment of CB CD34 + cells in the bone marrow of sublethally irradiated NOD/SCID interleukin (IL)-2Rγ null (NSG) mice. FUT7 also exhibited marginally-yet statistically significant-increased engraftment at 4 and 6 weeks after transplantation. In addition, FUT7-treated CB CD34
Introduction
Hematopoietic stem/progenitor cells (HSPCs) can be transplanted to the bone marrow of another individual following an intravenous infusion. This approach has been widely used in the treatment of various hematological disorders such as leukemia (Thomas 1995) . Human HSPCs are obtained from three different sources: Bone marrow, adult peripheral blood after mobilization and cord blood (CB), which is obtained from umbilical cords after delivery. Although there are >5 million unrelated bone marrow volunteer donors registered worldwide, finding a fully human leukocyte antigen (HLA)-matched unrelated donor remains a problem for many patients because of HLA polymorphism. Compared with bone marrow and peripheral blood, CB has several potential advantages: The wide and rapid availability of cells, the less stringent requirements for HLA matching between the donor and recipient and a lower risk of acute and chronic graft-versus-host disease (Gluckman et al. 1993; Wagner et al. 1996; Gluckman 2011) . Thus, CB-HSPCs have increasingly been used for bone marrow transplantations in recent years. However, compared with bone marrow and mobilized peripheral blood, CB has a lower number of cells collected in single donor units that limits its use in adults and higher weight children and also exhibits a relatively longer time to the engraftment in the bone marrow of recipients compared with other sources of HSPCs (Copelan 2006) .
Hematopoietic stem cell transplantation requires intravenous infusion of HSPCs from healthy donors into irradiated recipients. The infused HSPCs then home to and engraft in the bone marrow. Homing is the migration of circulating HSPCs to their bone marrow niches (Frenette et al. 1998; McEver 2002) . Homing relies on adhesion molecule interactions between the HSPCs and the endothelium of bone marrow. Selectins are a group of adhesion molecules including P-selectin, which is expressed on activated platelets and endothelial cells, and E-selectin, which is expressed on activated endothelial cells. Pand E-selectins bind to glycoconjugate ligands on leukocytes and HSPCs. The P-selectin glycoprotein ligand 1 (PSGL-1) is a major ligand on HSPCs for both P-and E-selectins (McEver 2002; Xia et al. 2002) . Selectin ligands must be α1,3 fucosylated to form terminal glycan determinants such as sialyl Lewis x (sLe x ). Inadequately α1,3 fucosylated CB-HSPCs bind poorly to both P-and E-selectins. sLe
x is synthesized by a series of glycosyltransferases, with the last step being catalyzed by α1,3-fucosyltransferases (FUTs) (McEver 2001) , which transfers a fucosyl moiety from guanosine diphosphate (GDP)-fucose to the core oligosaccharide structures. A significant percentage of CB-HSPCs exhibit homing defects because of defective fucosylation (Hidalgo et al. 2002; Xia et al. 2004) . Our published data show that ex vivo treatment of human CB-HSPCs cells with GDP-fucose and exogenous fucosyltransferase VI (FUT6) increases cell-surface sLe x determinants, augments binding to P-and E-selectins and enhances engraftment of CB-HSPCs in the bone marrow of irradiated non-obese diabetic/severe combined immune deficient (NOD/SCID) mice (Xia et al. 2004) . However, FUT6 is endogenously expressed in many cell types. Here, we report that surface fucosylation with fucosyltransferase VII (FUT7), which is primarily expressed in hematopoietic cells (Maly et al. 1996) , is effective in improving the function of selectin ligands on CB HSPCs.
Results
A higher concentration of FUT7 than FUT6 is required to achieve maximal surface fucosylation on CB CD34 + cells
Because FUT6 and FUT7 were provided from two separated sources with different protein concentrations, we determined their equivalent fucosylation activity using CB mononuclear cells (MNCs) isolated from fresh CB of healthy full-term newborns. 4 × 10 6 MNCs were treated with FUT6 from 0.087 to 44 µg/mL or with FUT7 from 0.3 to 18.75 µg/mL. Cells were then co-stained with a phycoerythrin (PE)-conjugated mouse monoclonal antibody (mAb) to human CD34, which is a marker of CB-HSPCs, and a rat mAb (immunoglobulin (IgM), HECA-452) to human cutaneous lymphocyte antigen, which is an established sLe x epitope (Xia et al. 2004) , followed by fluorescein isothiocyanate (FITC)-labeled mouse anti-rat IgM. Flow cytometry analysis indicated that both FUT6 and FUT7 treatment increased binding of HECA-452 to CD34 + cells in a dosedependent manner. Treatment with FUT6 at 2.75 µg/mL or FUT7 at 9.4 µg/mL resulted in maximal binding of HECA-452 to CD34 + cells. Therefore, these concentrations were used for the rest of the fucosylation experiments (Figure 1 ).
FUT7 exhibits an efficiency similar to that of FUT6 in adding fucosylation epitopes on CB CD34 + cells
We further compared the efficiency of FUT7 in fucosylating CB CD34 + cells. Consistent with the results of previous studies from our own group and others (Xia et al. 2004; Hidalgo and Frenette 2005) , 23% of CB CD34 + cells had low levels of HECA-452-positive epitopes (Figure 2A ). Treatment with either FUT6 or FUT7 equally enhanced the expression of HECA-452-positive epitopes on CB CD34 + cells (Figure 2A Figure 2B ). In addition, FUT7 and FUT6 were also able to add similar levels of HECA-452 epitopes on CD34 +
CD38
+ cells that primarily comprise hematopoietic progenitor cells ( Figure 2B ).
FUT7-fucosylated CB-HSPCs cells bind more to P-or E-selectin than cells treated with FUT6 Unlike FUT6, FUT7 is specifically expressed in hematopoietic cells including HSPCs (Sasaki et al. 1994; Maly et al. 1996; Kimura et al. 1997) . We asked whether FUT7 is more efficient than FUT6 at generating functional selectin ligands on CD34 + HSPCs. To address this question, fresh CB-MNCs were treated with either FUT6 or FUT7. After ex vivo fucosylation, the cells were subsequently incubated with anti-human CD34-PE and with a saturating amount of murine P-selectin/IgM chimera, E-selectin/IgM chimera or CD45-IgM (control) (Xia et al. 2002 (Xia et al. , 2004 . Bound P-or E-selectin was then detected by using goat anti-human IgM-FITC and analyzed on a FACSCalibur. The specificity of the selectin binding was verified by RB40.30, a blocking mAb to P-selectin, or 9A9, a blocking mAb to E-selectin ( Figure 3A and B).
Consistent with the published results (Xia et al. 2004) , our data indicate that 37% of control CB CD34 + cells did not bind to P-selectin ( Figure 3A ). In addition, 10% of CB CD34 + cells failed to bind to E-selectin ( Figure 3A ). Sham-treated (without GDP-fucose) CB CD34 + cells had no improvement in the binding to either P-or E-selectin. On the other hand, both FUT6-and FUT7-treated CB CD34 + cells exhibited greater binding to P-or E-selectin than the sham-treated cells 
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+ cells ( Figure 3A ). Significantly, FUT7-treated cells showed much greater binding to P-selectin than the FUT6-treated cells ( Figure 3B ). Moreover, FUT7 was significantly more effective than FUT6 in enhancing the binding of P-selectin to CD34 + CD38 −/low and CD34 + CD38 + cells ( Figure 3C ).
FUT7-treated CB CD34
+ cells accumulated more on P-and E-selectin-coated plates than FUT6-treated cells under flow conditions To determine whether FUT7-mediated fucosylation of CB CD34 + cells resulted in better interactions with selectins than FUT6-mediated fucosylation in a physiologically relevant setting, we compared the accumulation of FUT6-or FUT7-treated CB CD34 + cells on immobilized murine P-or E-selectin using a parallel-plate flow chamber assay (Xia et al. 2002 (Xia et al. , 2004 . CD34 + cells were purified from fresh CB using immunomagnetic microbeads. Sham-, FUT6-or FUT7-treated CB CD34 + cells (10 6 /mL) in Hanks' Balanced Salt Solution (HBSS) containing 0.5% human serum albumin (HSA) were perfused over P-or E-selectin-coated surfaces at 0.5 dyn/cm 2 . For the control experiments, cells were continuously maintained in the HBSS/HSA buffer containing 10 mM ethylenediaminetetraacetic acid (EDTA), which blocks the calcium-dependent interaction between selectins and ligands. We also utilized specific blocking mAb's to either murine P-or E-selectin. Our results show that both FUT6-and FUT7-treated CB CD34 + cells had greater binding to both P-and E-selectins under flow conditions than the sham-treated cells. Significantly, more FUT7-treated than FUT6-treated cells accumulated on both P-and E-selectin-coated plates ( Figure 4A and B) . The FUT7-treated cells also rolled more stably, as reflected by lower mean rolling velocities on P-selectin and on E-selectin (data not shown). Rolling was specific because mAb's to P-or E-selectin blocked the number of rolling cells (Figure 4 and B).
FUT7 treatment improves the engraftment of CB CD34
+ cells in the bone marrow of recipient mice To examine whether surface fucosylation of CB CD34 + cells leads to improved engraftment in bone marrow, sublethally irradiated NSG mice were transplanted with FUT6-, FUT7-or sham-treated CB CD34 + cells (Xia et al. 2004 ). Starting at 2 weeks post injection, mice were bled every 2 weeks and examined for circulating human CD45 + blood cells, which served as a surrogate marker for engraftment of donor cells in the bone marrow, by flow cytometry. Injection with either FUT6-or FUT7-treated CD34 + cells led to better engraftment in the recipients than observed with the injection of sham-treated CD34 + cells at 2, 4, 6 and 8 weeks after the transplantation ( Figure 5 ). The results with FUT6-treated cells are consistent with published studies (Xia et al. 2004; Robinson et al. 2012) . Interestingly, we observed a surge of hematopoietic recovery at 2 weeks post injection. Significantly, both FUT6 and FUT7 facilitated the recovery at this time point, which is likely caused by improved homing of fucosylated hematopoietic progenitor cells. Notably, however, mice receiving FUT7-treated CD34 + cells showed a significantly more enhanced hematopoietic recovery than mice receiving FUT6-treated cells as reflected by higher levels of human CD45 + cells in peripheral blood samples at 4 and 6 weeks ( Figure 5 ) post injection. These data indicate that FUT7-mediated surface fucosylation is as effective as FUT6 at enhancing engraftment and suggest that FUT7 may be more effective than FUT6 in improving early engraftment of fucosylated CD34 + cells under the conditions used in this study.
Enhanced homing of FUT7-treated CB CD34 + cells to bone marrow of NOD/SCID mice During transplantation, intravenously infused HSPCs first home to and then engraft in the bone marrow of the recipient. Interactions between selectins and their ligands are essential for homing (McEver 2002) . We determined whether the improved early engraftment by FUT7 treatment was due to improved homing of fucosylated CD34 + cells to the bone marrow. Our analyses indicate that 12-18 h after injection of FUT7-treated cells, there were more than three times more human CD45 + in the bone marrow of mice than in those that received shamtreated cells ( Figure 6A and B), indicating that FUT7 treatment + subset of cells that are either CD38 − or CD38 + were also analyzed for HECA-452 expression after fucosylation with either FUT6 or FUT7. The means ± SD of four independent experiments are presented (*P < 0.05, Student's t-test).
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+ cells significantly improved homing of CD34 + cells to the bone marrow of recipient mice.
Discussion
Interaction of selectins and their ligands expressed on HSPCs plays an important role in the recruitment of circulating HSPCs to the bone marrow of recipients (Frenette et al. 1998) . PSGL-1 (CD162) is the major physiological ligand on hematopoietic cells for P-and E-selectins (McEver 2001). Ligands for E-selectin include PSGL-1, E-selectin ligand-1 (ESL-1) and CD44 (McEver 2001) . Although the functional residues of these ligands for P-or E-selectin binding are different, the fucosylated determinant sLe x is required for both (McEver 2001) . However, 25% of CB CD34 + cells lack sLe x and are defective in their binding to either P-or E-selectin (Hidalgo et al. 2002; Xia et al. 2004) . A key component of sLe x for selectin binding is the α1,3-linked fucose whose synthesis is controlled by α1,3 fucosyltransferases. The endogenous α1,3 fucosyltransferase in leukocytes including CD34 + cells is FUT7 (Sasaki et al. 1994; Maly et al. 1996) . In vitro, we found that FUT7 is more effective than FUT6 in modifying functional selectin ligands on CB CD34 + cells, which include both CD34 + CD38 + and CD34 + CD38 − cells. Our in vivo data indicate that FUT7 treatment is at least as effective as FUT6 treatment in enhancing early engraftment of CB CD34 + cells in the bone marrow of recipients in this murine model. FUT6 and FUT7 belong to α1,3 fucosyltransferase family that can transfer fucose to 3′-sialylated type II acceptors observed with NeuAcα(2-3)Galβ(1-4)GlcNAc, which is the final step of synthesizing the sLe x antigen (Britten et al. 1998; de Vries et al. 2001 ). FUT7 and FUT6 have different specificities toward α2,3 sialylated type-II oligosaccharide acceptors. The hydroxyl groups at C-4 of Gal and C-3 of GlcNAc are essential for acceptor recognition for FUT7, and the acetamide group at C-2 of GlcNAc is essential for acceptor recognition for both FUT7 and FUT6. Therefore, FUT7 may have better specificity and capability than FUT6 to synthesize the functional sLe x . FUT7 is able to synthesize both di-and tri-fucosylated structures from mono-fucosylated precursors but preferentially fucosylates the distal GlcNAc within a polylactosamine chain. On the other hand, FUT6 lacks this specificity. In addition, the peptide sequences of selectin ligands on CB-HSPCs might also preferentially facilitate FUT7 activity. These substrate specificities may explain why FUT7-treated CB CD34 + cells have greater interactions with P-and E-selectins than FUT6-treated CB CD34 + cells do. Delayed bone marrow recovery following graft injection remains a clinical challenge for CB-HSPC transplantation. Neutrophil recovery often occurs 3-4 weeks post-CB-HSPC transplant (Wagner et al. 1996) . Delayed recovery is closely associated with early transplant-related complications and incidence of graft failure (Copelan 2006) . In the present study, we show that FUT7-treated CB CD34 + cells engrafted better in NSG mice than the FUT6-treated cells at 4-6 weeks post transplantation. During transplantation, homing of infused hematopoietic stem cells to the bone marrow niches is a primary step for successful hematopoietic reconstitution (Frenette et al. 1998) . Our data support that FUT7 improves binding of fucosylated CB CD34 + cells to P-and E-selectins and enhances + cells engraft faster than FUT6-treated cells. After injection of cells treated with FUT6 at 2.75 µg/mL or FUT7 at 9.4 µg/mL for 30 min, the presence of human leukocytes in the peripheral blood was measured using flow cytometry to detect anti-human CD45, a pan leukocyte marker, in samples collected at the indicated time points. Data are means ± SEM (*P < 0.05, n = 5, Mann-Whitney U-test).
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homing of fucosylated CB CD34
+ cells to the bone marrow of recipients. These data strongly support that enhanced selectinmediated adhesion between fucosylated CB CD34 + cells and vascular endothelial cells in the bone marrow functions as a major factor contributing to the enhanced in vivo engraftment.
Human hematopoietic cells express FTIV, FUT7 and FTIX, but not FUT6. Accordingly, FUT7 plays a major role in the biosynthesis of selectin ligands (Maly et al. 1996) . The physiological relevance of FUT6 in selectin-ligand function remains to be defined (Sasaki et al. 1994; Kimura et al. 1997) . FTVI is effective in preclinical models of hematopoietic stem cell engraftment (Xia et al. 2002; Robinson et al. 2012) and is currently in clinical trials for enhancement of CB engraftment in patients with hematological malignancies. FUT7 treatment offers another promising approach to overcome the critical clinical problem of delayed recovery post transplantation of HSPCs.
Materials and methods
Human CB samples Fresh CB samples were obtained from healthy full-term newborns who were delivered at the University of Oklahoma Health Sciences Center. This protocol was approved by the Institutional Review Boards of University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation. Red blood cells were first allowed to sediment out by incubation with equal volumes of 6% dextran 70 in 0.9% sodium chloride (McGraw Irvine, CA). MNCs were isolated after centrifugation at 400 × g over Ficoll-Hypaque (density [d] = 1.077 g/mL, Mediatech, Inc., Manassas, VA). For some experiments, CD34 + cells were isolated from the MNC fraction using the CD34 isolation minimagnetic-activated cell sorting (MACS) kit following the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the isolated CD34 + cells was 95% as determined by using flow cytometry.
Surface fucosylation
Ex vivo cell-surface fucosylation was performed based on our published method (Xia et al. 2004) . Briefly, to introduce an α1,3-linked fucose to cell-surface glycans, 4 × 10 6 CB MNCs were treated with 1 mM GDP-fucose (Kyowa Hakko Kirin Co., Ltd., Japan), FUT6 (America Stem Cell, Inc., CA) or FUT7 (Kyowa Hakko Kirin Co., Ltd., Japan) in 0.2 mL HBSS (MediaTech, Manassas, VA) containing 0.1% HSA (SigmaAldrich, St Louis, MO) for 30 min at 37°C in a humidified atmosphere containing 5% CO 2 . Sham-treated cells were treated identically except that GDP-fucose was not added. We did not include manganese, an activating cofactor for fucosyltransferase, to avoid potential cytotoxicity (Sackstein et al. 2008) .
Flow cytometry
Flow cytometry analyses were performed based on our published methods (Xia et al. 2002 (Xia et al. , 2004 . For all flow cytometry analyses, Fc receptors on CB cells were first blocked with Fc receptor blocker (Accurate Chemical & Scientific Corporation, New York, NY). To measure sLe x determinants, CB MNCs were incubated with PE-conjugated mouse anti-human CD34 mAb (15 µg/mL, BD Biosciences, San Jose, CA) or control PE-mouse IgG (IgG1) with FITC-conjugated rat anti-human sLe x mAb HECA-452 (IgM, 15 µg/mL, BioLegend, San Diego, CA) or control FITC-conjugated rat IgM. For the P-and E-selectin-binding assays, CB MNCs were incubated with murine P-selectin/human IgM chimera (P-selectin/IgM) and murine E-selectin/human IgM chimera (E-selectin/IgM). Murine CD45/human IgM chimera was used as control (Xia et al. 2002 (Xia et al. , 2004 . The chimeras were obtained from conditioned medium of COS-7 cells that were transfected, respectively, with pCDM8 vectors encoding each molecule (Dr. John B. Lowe, Genentech, South San Francisco, CA). Incubations were performed for 20 min at 4°C for each step. P-and E-selectin binding was then detected with secondary goat anti-human IgM-FITC (5 µg/mL, Chemicon International, Temecula, CA). A saturating amount of P-and E-selectins, determined by measuring binding over a range of P-and E-selectin concentrations, was used in all experiments. In the control experiments, P-selectin binding was measured in the presence of RB40.34 (Dr. Dietmar Vestweber, Max Planck Institute for Molecular Biomedicine, Munster, Germany), a blocking mAb to murine P-selectin. The blocking mAb for E-selectin binding was 9A9, Dr. Barry Wolitzky, Roche Research Center, Hoffmann-La Roche, Basel, Switzerland.
All flow cytometric analyses were carried out on a FACSCalibur (BD Biosciences). Data were collected and analyzed by using the CellQuestpro program (BD Biosciences). FTVII enhances selectin-ligand function on CB CD34 + cells
